T-cell lymphomaDeveloping CAR T-cells for T-lineage malignancies requires minimizing fratricide of engineered T-cells and mitigating the risk of T-cell aplasia, which may be caused by the off-tumor activity of CAR T-cells. We have developed and optimized for clinical evaluation a CAR targeting...
CAR-T 细胞疗法，全称 “嵌合抗原受体 T 细胞疗法”，其原理是通过插入 CAR 对患者的 T 细胞进行基因改造，改造后的T细胞就如同被精准编程的“抗癌特种兵”，能够精准靶向癌细胞。十二年前，年仅5岁的白血病患儿艾米莉(Emily)，在CAR-T治疗23天后，成功实现了“临床治愈”，此后更是创造了无癌生存长达12年的生...
Adoptive cell therapies (ACTs) have been used to treat cancer for over 30 years. The rationale that led to the chimeric antigen receptor-modified T (CAR T)-cells was to overcome the HLA restriction, the effective presentation of target epitopes, and the lack of a broad TCR gene repertoire ...
N. Chimeric antigen receptor T-cell therapies for lymphoma. Nat. Rev. Clin. Oncol. 15, 31–46 (2018). CAS PubMed Google Scholar Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)....
Chen, X. et al. (2023) 'Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.,' Journal of Clinical Oncology, 41(16_su...
如果您也饱受血液肿瘤或实体瘤困扰，且想寻求CAR-T疗法的帮助，可将治疗经历、近期病理和影像学检查结果、血液检查结果等，提交至医学部，进行初步评估。参考资料 [1]Cwynarski K,et al.TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial[J]. Nature Medicine, 2024: 1-7.https...
2025年5月12日,全球首位接受CAR-T细胞治疗并成功治愈急性淋巴细胞白血病的“抗癌小战士”——艾米莉・怀特海德(Emily Whitehead),在社交媒体上向世界宣告:“13 years cancer free yesterday + celebrated being 20 today(昨天是癌症康复...
新闻来源:UCLA opens CAR T clinical trial targeting most common types of lymphoma and leukemia 2019年10月,加州大学洛杉矶分校琼森综合癌症中心启动了一项开创性的嵌合抗原受体(CAR)T细胞(CAR-T)免疫疗法临床试验。在这项临床试验中,CAR-T细胞将通过同时识别在B细胞淋巴瘤和白血病细胞表面上表达的两个靶标--- ...
16. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells [J]. Blood, 2012, 119(12): p. 2709-20. doi: 10.1182/blood-2011-10-...
“ The frequency of differentiated CD3+CD27-CD28- T cells predicts response to CART cell therapy in diffuse large B-cell lymphoma ”的研究报告中,来自维也纳医科大学等机构的科学家们通过研究发现了一种针对CAR-T细胞疗法临床反应的高度潜在的生物标志物,同时还描述了最佳使用这种新型疗法用来治疗淋巴瘤的先决...